<DOC>
	<DOCNO>NCT02065882</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics , efficacy safety BT524 patient congenital fibrinogen deficiency .</brief_summary>
	<brief_title>Pharmacokinetic , Efficacy Safety BT524 Patients With Congenital Fibrinogen Deficiency</brief_title>
	<detailed_description>The present study design prospective , open-label , multicentre , phase I/III study investigate 14 day single-dose pharmacokinetic property , efficacy safety BT524 follow intravenous administration treatment prophylaxis bleeding patient congenital afibrinogenemia severe congenital hypofibrinogenemia .</detailed_description>
	<mesh_term>Afibrinogenemia</mesh_term>
	<criteria>Known congenital afibrinogenemia severe congenital hypofibrinogenemia Plasma fibrinogen activity ≤ 0.5 g/l antigen ≤ 0.5 g/l Male female Age 6 75 year , first ten patient 18 year old Presumed compliant study procedure terminate study schedule Willing able hospitalize 3 day pharmacokinetic assessment ( applicable ) Willing able hospitalize required case intervention ( e.g. , surgical procedure , major bleeds ) Written informed consent patient , his/her parent patient 's legal / authorize representative applicable Known congenital dysfibrinogenemia Known bleeding disorder congenital fibrinogen deficiency History esophageal variceal bleed Known presence history venous/arterial thrombosis thromboembolic event precede 6 month Known presence history fibrinogen inhibitory antibody Known presence history hypersensitivity human fibrinogen human plasma protein e.g. , immunoglobulin , vaccine hypersensitivity excipients Known positive serology HIV1 HIV2 Clinically relevant biochemical hematological finding ( except due underlie disease emergency bleed ) outside normal range ( investigator 's discretion ) Clinically relevant pathological finding physical examination include electrocardiogram ( ECG ) Treatment fibrinogen concentrate and/or fibrinogencontaining product within 2 week prior infusion BT524 Concomitant medication interact relevantly coagulation system ( e.g. , low molecular weight heparin , unfractioned heparin , factor Xa inhibitor , factor IIa inhibitor PY12 inhibitor ) within 2 week prior infusion BT524 Recent vaccination ( within 3 week prior infusion ) Body weight 22 kg End stage disease Abuse drug Unable understand follow study requirement Participation another interventional clinical study within 30 day enter study study Pregnant/ nursing woman , woman childbearing potential use reliable/ effective contraceptive method ( ) study least one month last administration study drug ( e.g. , oral/ injectable/ implantable/ insertable/ topical hormonal contraceptive , intrauterine device , female sterilization , partner 's vasectomy condom ) Any condition , investigator 's judgment , could impact patient 's safety study result Elective surgery 14 day PK blood sample period Acute infection Clinically relevant increase decrease body temperature Actively bleed anticipate bleeding ( include female menorrhea ) time point within 7 day prior infusion BT524 Surgery within 7 day prior infusion BT524 Immobilization within 7 day prior infusion BT524 Intake alcohol significantly increase intake caffeine containing product within 24 hour prior infusion BT524 Blood donation comparable blood loss within 60 day prior infusion BT524 Excessive physical exercise ( extreme sport activity , sauna ) within 72 hour prior infusion BT524</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>fibrinogen , bleeding ,</keyword>
</DOC>